Plus Therapeutics, Inc. traded at $0.27 this Wednesday February 11th, increasing $0.01 or 3.04 percent since the previous trading session. Looking back, over the last four weeks, Plus Therapeutics gained 44.69 percent. Over the last 12 months, its price fell by 75.80 percent. Looking ahead, we forecast Plus Therapeutics, Inc. to be priced at 1.81 by the end of this quarter and at 1.65 in one year, according to Trading Economics global macro models projections and analysts expectations.
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.